Sarepta Therapeutics Inc (SRPT)
Net profit margin
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 235,239 | 121,845 | 47,297 | 16,897 | -535,977 | -690,876 | -907,677 | -1,115,218 | -703,488 | -716,225 | -506,631 | -356,555 | -418,780 | -486,116 | -634,471 | -703,886 | -554,128 | -600,514 | -530,341 | -655,924 |
| Revenue (ttm) | US$ in thousands | 1,901,979 | 1,640,348 | 1,504,993 | 1,403,300 | 1,243,336 | 1,104,982 | 1,003,434 | 975,683 | 933,013 | 876,047 | 835,184 | 765,786 | 701,887 | 645,564 | 600,082 | 573,356 | 540,099 | 495,074 | 450,191 | 407,496 |
| Net profit margin | 12.37% | 7.43% | 3.14% | 1.20% | -43.11% | -62.52% | -90.46% | -114.30% | -75.40% | -81.76% | -60.66% | -46.56% | -59.66% | -75.30% | -105.73% | -122.77% | -102.60% | -121.30% | -117.80% | -160.96% |
December 31, 2024 calculation
Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $235,239K ÷ $1,901,979K
= 12.37%
Sarepta Therapeutics Inc experienced a significant improvement in its net profit margin trend over the period from March 31, 2020, to December 31, 2024. The company initially posted negative net profit margins, indicating losses exceeding revenue. However, starting from March 31, 2024, the net profit margin turned positive, reaching 1.20%, and continued to rise steadily to 12.37% by December 31, 2024.
The positive net profit margins from March 31, 2024, to December 31, 2024, signify that the company's profitability improved, indicating that Sarepta Therapeutics Inc was able to generate more income than its expenses during these periods. This positive trend suggests enhanced operational efficiency and effective cost management, potentially demonstrating the company's ability to leverage its resources to drive profitability.
Overall, the transition from negative to positive net profit margins reflects a positive turnaround for Sarepta Therapeutics Inc, showcasing improved financial performance and potentially boosting investor confidence in the company's financial health and sustainability.
Peer comparison
Dec 31, 2024